SCHEMBL6281582

SCHEMBL6281582

COC(=O)c1cc2ncccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.50
ALOX15 P16050 1/20 0.50
KDM4E B2RXH2 5/20 0.43
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPK1 P28482 3/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 2/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17749939 0.82 ALDH1A1 (0.44) KDM4ENPC1RAB9AMAPTSMN1; SMN2
SCHEMBL29689092 0.80 KDM4E (0.49) HTTALOX15KDM4ENPC1RAB9A
SCHEMBL4128614 0.80 KDM4E (0.49) HTTALOX15KDM4ENPC1RAB9A
SCHEMBL29686936 0.80 CHRNB2 (0.44) KDM4ENPC1RAB9AMAPTSMN1; SMN2
SCHEMBL24776512 0.79 MEN1 (0.40) HTTNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL30731161 0.75 HTT (0.50) HTTALOX15KDM4ENPC1RAB9A
SCHEMBL24776328 0.74 FAAH (0.41) MAPTALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3529069 0.73 MAPT (0.69) HTTKDM4ENPC1RAB9AMAPT
SCHEMBL30770835 0.73 MAPT (0.69) HTTKDM4ENPC1RAB9AMAPT
SCHEMBL4810941 0.72 CA12 (0.52) HTTKDM4ENPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878705-B2 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents PFIZER (US) 2005-04-12 US disclosed
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY 2004-12-23 US disclosed
EP-1465895-A2 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-13 EP disclosed
WO-2003059911-A2 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS IL4, ZC3HAV1, IRF3 HTT 4197/4885ALOX15 4832/4885KDM4E 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.